Table 1.
Demographic and Clinical Characteristics at Baseline
| Characteristic | Intent-to-treat Population | HRQoL Analysis Population | ||
|---|---|---|---|---|
| EPd (n = 60) | Pd (n = 57) | EPd (n = 55) | Pd (n = 51) | |
| Age at baseline, y | ||||
| Mean (SD) | 66.2 (9.9) | 65.5 (9.9) | 66.9 (9.3) | 65.5 (10.3) |
| Sex, n (%) | ||||
| Female | 28 (46.7) | 22 (38.6) | 26 (47.3) | 21 (41.2) |
| Male | 32 (53.3) | 35 (61.4) | 29 (52.7) | 30 (58.8) |
| Race, n (%) | ||||
| Asian | 15 (25.0) | 9 (15.8) | 15 (27.3) | 8 (15.7) |
| White | 45 (75.0) | 45 (78.9) | 40 (72.7) | 41 (80.4) |
| Black or African American | - | 1 (1.8) | - | - |
| Other | - | 2 (3.5) | - | 2 (3.9) |
| Region, n (%) | ||||
| North America | 3 (5.0) | 7 (12.3) | 3 (5.5) | 6 (11.8) |
| Europe | 44 (73.3) | 43 (75.4) | 39 (70.9) | 39 (76.5) |
| Japan | 13 (21.7) | 7 (12.3) | 13 (23.6) | 6 (11.8) |
| ECOG PS at baseline, n (%) | ||||
| 0 | 28 (46.7) | 23 (40.4) | 26 (47.3) | 21 (41.2) |
| 1 | 28 (46.7) | 26 (45.6) | 25 (45.5) | 23 (45.1) |
| 2 | 4 (6.7) | 8 (14.0) | 4 (7.3) | 7 (13.7) |
| Prior therapy lines, n (%) | ||||
| 2–3 | 37 (61.7) | 35 (61.4) | 34 (61.8) | 32 (62.7) |
| ≥4 | 23 (38.3) | 22 (38.6) | 21 (38.2) | 19 (37.3) |
| ISS stage, n (%) | ||||
| I–II | 52 (86.7) | 51 (89.5) | 48 (87.3) | 45 (88.2) |
| III | 8 (13.3) | 6 (10.5) | 7 (12.7) | 6 (11.8) |
ECOG PS = Eastern Cooperative Oncology Group performance status; EPd = elotuzumab + pomalidomide + dexamethasone; HRQoL = health-related quality of life; ISS = International Staging System; Pd = pomalidomide + dexamethasone; SD = standard deviation.